Merck KGaA lands rights to 3rd F-star oncology bispecific antibody

Merck KGaA has exercised its option on a third immuno-oncology bispecific from F-star Therapeutics. The agreement follows the expansion of a deal last year to give Merck a time-limited option on two more assets.